litlas
Log inCreate account

Christopher J. Lord

Active 1997–2025

157
Papers
43,526
Citations
99
h-index
150
i10-index

Citations

Citations per year for Christopher J. Lord1943: 1 citations1982: 1 citations1990: 1 citations1994: 1 citations1996: 3 citations1997: 3 citations1998: 17 citations1999: 8 citations2000: 20 citations2001: 38 citations2002: 14 citations2003: 8 citations2004: 16 citations2005: 38 citations2006: 60 citations2007: 81 citations2008: 151 citations2009: 216 citations2010: 397 citations2011: 362 citations2012: 392 citations2013: 453 citations2014: 492 citations2015: 470 citations2016: 534 citations2017: 640 citations2018: 691 citations2019: 1,881 citations2020: 2,336 citations2021: 2,227 citations2022: 1,905 citations2023: 1,349 citations2024: 1,922 citations2025: 1,009 citations2026: 17 citations1944–1981: no citations, so these years are not shown1983–1989: no citations, so these years are not shown1991–1993: no citations, so these years are not shown1995: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 5,120 citing papers, 27% of this breakdownChina: 2,062 citing papers, 10.8% of this breakdownUnited Kingdom: 1,911 citing papers, 10.1% of this breakdownItaly: 923 citing papers, 4.9% of this breakdownGermany: 913 citing papers, 4.8% of this breakdownCanada: 792 citing papers, 4.2% of this breakdownFrance: 715 citing papers, 3.8% of this breakdownSpain: 572 citing papers, 3% of this breakdownAustralia: 530 citing papers, 2.8% of this breakdownNetherlands: 523 citing papers, 2.7% of this breakdownJapan: 462 citing papers, 2.4% of this breakdownSwitzerland: 363 citing papers, 1.9% of this breakdown
0%27%Other 21.6%

Institutions

Fields

  • Medicine50.6%
  • Biochemistry, Genetics and Molecular Biology43.1%
  • Immunology and Microbiology2.9%
  • Computer Science0.8%
  • Engineering0.7%
  • Chemistry0.4%
  • Other1.5%

Topics

  • PARP inhibition in cancer therapy10.6%
  • DNA Repair Mechanisms8.8%
  • Cancer Genomics and Diagnostics3.6%
  • CRISPR and Genetic Engineering3%
  • Cancer-related Molecular Pathways2.8%
  • BRCA gene mutations in cancer2.6%
  • Other68.6%

Coauthors

All papers

Open in search
  1. PARP inhibitors: Synthetic lethality in the clinic

    Authors: Christopher J. Lord, Alan Ashworth - Science 2017 cited by 2,937

  2. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

    Authors: Hannah Farmer, Nuala McCabe, Christopher J. Lord, Andrew Tutt, Damian A. Johnson, Tobias B. Richardson, Manuela Santarosa, Krystyna J. Dillon, Ian Hickson, Charlotte Knights, Niall M.B. Martin, Stephen P. Jackson, Graeme C.M. Smith, Alan Ashworth - Nature 2005 cited by 6,735

  3. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

    Authors: Joaquı́n Mateo, Suzanne Carreira, Shahneen Sandhu, Susana Miranda, Helen Mossop, Raquel Pérez-López, Daniel Nava Rodrigues, Dan R. Robinson, Aurelius Omlin, Nina Tunariu, Gunther Boysen, Núria Porta, Penny Flohr, Alexa Gillman, Ines Figueiredo, Claire Paulding, George Seed, Suneil Jain, Christy Ralph, Andrew Protheroe, Syed A. Hussain, Robert J. Jones, Tony Elliott, Ursula McGovern, Diletta Bianchini, Jane Goodall, Zafeiris Zafeiriou, Chris T. Williamson, Roberta Ferraldeschi, Ruth Riisnaes, Bernardette Ebbs, Gemma Fowler, Desamparados Roda, Wei Yuan, Yi‐Mi Wu, Xuhong Cao, Rachel Brough, Helen N. Pemberton, Roger A’Hern, Amanda Swain, Lakshmi P. Kunju, Rosalind A. Eeles, Gerhardt Attard, Christopher J. Lord, Alan Ashworth, Mark A. Rubin, Karen E. Knudsen, Felix Y. Feng, Arul M. Chinnaiyan, Emma Hall, Johann S. de Bono - New England Journal of Medicine 2015 cited by 2,187

  4. Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer

    Authors: María Teresa Herrera-Abreu, Marta Palafox, Uzma Asghar, Martín A. Rivas, Rosalind Cutts, Isaac García-Murillas, Alex Pearson, Marta Guzmán, Olga Rodríguez, Judit Grueso, Meritxell Bellet, Javier Cortés, Richard Elliott, Sunil Pancholi, Christopher J. Lord, José Baselga, Mitch Dowsett, Lesley‐Ann Martin, Nicholas C. Turner, Violeta Serra - Cancer Research 2016 cited by 779

  5. A decade of clinical development of PARP inhibitors in perspective

    Authors: J. Mateo, Christopher J. Lord, Violeta Serra, Andrew Tutt, Judith Balmañà, Marta Castroviejo‐Bermejo, Cristina Cruz, Ana Oaknin, Stan B. Kaye, Johann S. de Bono - Annals of Oncology 2019 cited by 730

  6. BRCAness revisited

    Authors: Christopher J. Lord, Alan Ashworth - Nature reviews. Cancer 2016 cited by 1,250

  7. Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance

    Authors: Diana Zatreanu, Helen M.R. Robinson, Omar Alkhatib, Marie Boursier, Harry Finch, Lerin Geo, Diego Grande, Vera Grinkevich, Robert A. Heald, Sophie Langdon, Jayesh B. Majithiya, Claire McWhirter, Niall M.B. Martin, Shaun Moore, Joana Neves, Eeson Rajendra, Marco Ranzani, Theresia A. Schaedler, Martin L. Stockley, Kimberley A. Wiggins, Rachel Brough, Sandhya Sridhar, Aditi Gulati, Nan Shao, Luned Badder, Daniela Novo, Eleanor Knight, Rebecca Marlow, Syed Haider, Elsa Callén, Graeme Hewitt, Joost Schimmel, Remko Prevo, Christina Alli, Amanda Ferdinand, Cameron Bell, Peter Blencowe, Christopher Bot, Mathew Calder, Mark Charles, Jayne Curry, Tennyson Ekwuru, Katherine Ewings, Wojciech Krajewski, Ellen MacDonald, Hollie McCarron, Leon Pang, Chris Pedder, Laurent Rigoreau, Martin E. Swarbrick, Ed Wheatley, Simon N. Willis, Ai Ching Wong, André Nussenzweig, Marcel Tijsterman, Andrew Tutt, Simon J. Boulton, Geoff S. Higgins, Stephen J. Pettitt, Graeme C.M. Smith, Christopher J. Lord - Nature Communications 2021 cited by 350

  8. The DNA damage response and cancer therapy

    Authors: Christopher J. Lord, Alan Ashworth - Nature 2012 cited by 1,829

  9. ADP‐ribosyltransferases, an update on function and nomenclature

    Authors: Bernhard Lüscher, Ivan Ahel, Matthias Altmeyer, Alan Ashworth, Péter Bai, Paul Chang, Michael S. Cohen, Daniela Corda, Françoise Dantzer, Matthew D. Daugherty, Ted M. Dawson, Valina L. Dawson, Sebastian Deindl, Anthony R. Fehr, Karla L. H. Feijs, Dmitri V. Filippov, Jean‐Philippe Gagné, Giovanna Grimaldi, Sebastian Guettler, Nícolas C. Hoch, Michael O. Hottiger, Patricia Korn, W. Lee Kraus, Andreas G. Ladurner, L. Lehtiö, Anthony K. L. Leung, Christopher J. Lord, Aswin Mangerich, Ivan Matić, Jason Matthews, George‐Lucian Moldovan, Joel Moss, Gioacchino Natoli, Michael L. Nielsen, Mario Niepel, F. Nolte, John M. Pascal, Bryce M. Paschal, Krzysztof Pawłowski, Guy G. Poirier, Susan Smith, Gyula Timinszky, Zhao‐Qi Wang, José Yélamos, Xiaochun Yu, Roko Žaja, Mathias Ziegler - FEBS Journal 2021 cited by 327

  10. The shieldin complex mediates 53BP1-dependent DNA repair

    Authors: Sylvie M. Noordermeer, Salomé Adam, Dheva Setiaputra, Marco Barazas, Stephen J. Pettitt, Alexanda K. Ling, Michele Olivieri, Alejandro Álvarez-Quilón, Nathalie Moatti, Michal Zimmermann, Stefano Annunziato, Dragomir B. Krastev, Feifei Song, Inger Brandsma, Jessica Frankum, Rachel Brough, Alana Sherker, Sébastien Landry, Rachel K. Szilard, Meagan Munro, Andrea McEwan, Théo Goullet de Rugy, Zhen‐Yuan Lin, Traver Hart, Jason Moffat, Anne‐Claude Gingras, Alberto Martín, Haico van Attikum, Jos Jonkers, Christopher J. Lord, Sven Rottenberg, Daniel Durocher - Nature 2018 cited by 675

  11. Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance

    Authors: Stephen J. Pettitt, Dragomir B. Krastev, Inger Brandsma, Amy Dréan, Feifei Song, Radoslav Aleksandrov, Maria I. Harrell, Malini Menon, Rachel Brough, James Campbell, Jessica Frankum, Michael Ranes, Helen N. Pemberton, Rumana Rafiq, Kerry Fenwick, Amanda Swain, Sebastian Guettler, Jung-Min Lee, Elizabeth M. Swisher, Stoyno Stoynov, Kosuke Yusa, Alan Ashworth, Christopher J. Lord - Nature Communications 2018 cited by 447

  12. Targeting the DNA damage response in immuno-oncology: developments and opportunities

    Authors: Roman M. Chabanon, Mathieu Rouanne, Christopher J. Lord, Jean‐Charles Soria, Philippe Pasero, Sophie Postel‐Vinay - Nature reviews. Cancer 2021 cited by 323

  13. ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer

    Authors: Rowan Miller, Alexandra Léary, Clare L. Scott, Violeta Serra, Christopher J. Lord, David D.L. Bowtell, David K. Chang, Dale W. Garsed, Jos Jonkers, Jonathan A. Ledermann, Serena Nik‐Zainal, Isabelle Ray‐Coquard, Sohrab P. Shah, Xavier Matías‐Guiu, Elizabeth M. Swisher, Lucy Yates - Annals of Oncology 2020 cited by 481

  14. Structural basis for allosteric PARP-1 retention on DNA breaks

    Authors: Levani Zandarashvili, Marie-France Langelier, Uday Kiran Velagapudi, Mark A. Hancock, Jamin D. Steffen, Ramya Billur, Zain M. Hannan, Andrew J. Wicks, Dragomir B. Krastev, Stephen J. Pettitt, Christopher J. Lord, Tanaji T. Talele, John M. Pascal, Ben E. Black - Science 2020 cited by 331

  15. PARP inhibition enhances tumor cell–intrinsic immunity in ERCC1-deficient non–small cell lung cancer

    Authors: Roman M. Chabanon, Gareth Muirhead, Dragomir B. Krastev, Julien Adam, Daphné Morel, Marlène Garrido, Andrew Lamb, Clémence Henon, Nicolas Dorvault, Mathieu Rouanne, Rebecca Marlow, Ilirjana Bajrami, Marta Llorca Cardeñosa, Asha Konde, Benjamin Besse, Alan Ashworth, Stephen J. Pettitt, Syed Haider, Aurélien Marabelle, Andrew Tutt, Jean‐Charles Soria, Christopher J. Lord, Sophie Postel‐Vinay - Journal of Clinical Investigation 2018 cited by 324

  16. ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A

    Authors: Chris T. Williamson, Rowan Miller, Helen N. Pemberton, Samuel E. Jones, James Campbell, Asha Konde, Nicholas Badham, Rumana Rafiq, Rachel Brough, Aditi Gulati, Colm J. Ryan, Jeffrey C. Francis, Peter B. Vermulen, Andrew R. Reynolds, Philip M. Reaper, John R. Pollard, Alan Ashworth, Christopher J. Lord - Nature Communications 2016 cited by 387

  17. Clinical BRCA1/2 Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance

    Authors: Stephen J. Pettitt, Jessica Frankum, Marco Punta, Stefano Lise, John Alexander, Yi Chen, Timothy A. Yap, Syed Haider, Andrew Tutt, Christopher J. Lord - Cancer Discovery 2020 cited by 184

  18. Resistance to therapy caused by intragenic deletion in BRCA2

    Authors: Stacey L. Edwards, Rachel Brough, Christopher J. Lord, Rachael Natrajan, Radost Vatcheva, Douglas A. Levine, Jeff Boyd, Jorge S. Reis‐Filho, Alan Ashworth - Nature 2008 cited by 1,012

  19. Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors

    Authors: Timothy A. Yap, Brent O’Carrigan, Marina S. Penney, Joline S.J. Lim, Jessica Brown, Maria J. de Miguel, Nina Tunariu, Raquel Pérez-López, Daniel Nava Rodrigues, Ruth Riisnaes, Ines Figueiredo, Suzanne Carreira, Brian Hare, K. Mcdermott, Saira Khalique, Chris T. Williamson, Rachael Natrajan, Stephen J. Pettitt, Christopher J. Lord, Udai Banerji, John R. Pollard, Juanita Lopez, Johann S. de Bono - Journal of Clinical Oncology 2020 cited by 248

  20. Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?

    Authors: Alan Ashworth, Christopher J. Lord - Nature Reviews Clinical Oncology 2018 cited by 421

  21. Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition

    Authors: Nuala McCabe, Nicholas C. Turner, Christopher J. Lord, Katarzyna Kluzek, Aneta Białkowska, Sally Swift, Sabrina Giavara, Mark J. O’Connor, Andrew Tutt, Małgorzata Z. Zdzienicka, Graeme C.M. Smith, Alan Ashworth - Cancer Research 2006 cited by 1,305

  22. Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial

    Authors: Suzanne Carreira, Núria Porta, Sara Arce‐Gallego, George Seed, Alba Llop‐Guevara, Diletta Bianchini, Pasquale Rescigno, Alec Paschalis, Cláudia Bertan, Chloe Baker, Jane Goodall, Susana Miranda, Ruth Riisnaes, Ines Figueiredo, Ana Ferreira, Rita Pereira, Mateus Crespo, Bora Gürel, Daniel Nava Rodrigues, Stephen J. Pettitt, Wei Yuan, Violeta Serra, Jan Rekowski, Christopher J. Lord, Emma Hall, Joaquı́n Mateo, Johann S. de Bono - Cancer Discovery 2021 cited by 162

  23. Defective ALC1 nucleosome remodeling confers PARPi sensitization and synthetic lethality with HRD

    Authors: Graeme Hewitt, Valérie Borel, Sandra Segura‐Bayona, Tohru Takaki, Phil Ruis, Roberto Bellelli, Laura C. Lehmann, Lucia Sommerová, Aleksandra Vančevska, Antonia Tomás‐Loba, Kang Zhu, C.D.O. Cooper, Kasper Fugger, Harshil Patel, Robert Goldstone, Deborah Schneider-Luftman, Ellie Herbert, Gordon Stamp, Rachel Brough, Stephen J. Pettitt, Christopher J. Lord, Stephen C. West, Ivan Ahel, Dragana Ahel, J. Ross Chapman, Sebastian Deindl, Simon J. Boulton - Molecular Cell 2020 cited by 164

  24. The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin

    Authors: Dragomir B. Krastev, Shudong Li, Yilun Sun, Andrew J. Wicks, Gwendoline Hoslett, Daniel Weekes, Luned Badder, Eleanor Knight, Rebecca Marlow, Mercedes Pardo, Lu Yu, Tanaji T. Talele, Jiří Bártek, Jyoti S. Choudhary, Yves Pommier, Stephen J. Pettitt, Andrew Tutt, Kristijan Ramadan, Christopher J. Lord - Nature Cell Biology 2022 cited by 162